Acquisition wake Deallus recently exited via acquisition by GlobalData and TXM Group in January 2025, signaling a potential shift in client relationships, integration capabilities, and expanded service footprints that could open upsell opportunities in competitive intelligence, market dynamics, and life sciences consulting.

Growth potential With a revenue range of 25 to 50 million and a global life sciences focus, there is potential to discuss expanded CI offerings, continuous market landscaping, and forecasting services to current clients as larger enterprise needs evolve post-acquisition.

Therapy depth Specialization across neuroscience, oncology, rare diseases, and vaccines positions Deallus to cross-sell deep-dive services in R&D strategy, portfolio optimization, pricing and access, and medical affairs to pharma, biotech, and med-tech clients.

Strategic footprint Longstanding relationships with global pharma and emerging biopharma indicate opportunities to offer integrated CI-driven solutions, workshops, and long-term advisory engagements that align with clients’ strategic planning cycles.

Talent leverage A multidisciplinary team of commercial scientists and a diverse, inclusive culture provides a strong value proposition for selling ongoing client partnerships, knowledge transfer programs, and upskilling services to sustain competitive advantage.